Background: In the diagnosis of prostatic diseases, the need for markers other than prostate specific antigen (PSA) has been increasing in recent years. So, we aimed to determine the predictive value, the neutrophil lymphocyte ratio, platelet-to-lymphocyte ratio and mean platelet volume before prostate biopsy in predicting the results of pathology. Transrectal ultrasound-guided biopsy of the prostate was performed because of high PSA values and compared values of these parameters to predict of pathology results. Methods: 2715 patients who underwent 10 -12 quadrant transrectal ultrasound-guided prostate biopsies between January 2008 and January 2018 have been evaluated retrospectively. Patients were divided into groups according to the biopsy pathology results by benign (group 1), atypical small acinar proliferation (ASAP) (group 2) and prostate cancer (group 3). A total of 204 patients who were benign prostate hyperplasia in 71 patients (34.8%), atypical small acinar proliferation in 80 (39.21%) and prostate adenocarcinoma (PCa) in 53 patients (25.98%) were included in the study by systematic sampling. Before the biopsy total PSA (tPSA), free PSA (fPSA), rate of percentage of free to total prostate specific antigen (f/tPSA) rate, PSA density (PSA-D), white blood cell (WBC) count, blood neutrophil count (NC), blood lymphocyte count (LC), neutrophil lymphocyte ratio (NLR), mean platelet volume (MPV), platelet count (PLT) and platelet-to-lymphocyte ratio (PLR) were measured and compared in all groups. Differences in continuous variables were assessed using the ANOVA. Logistic regression was used to analyze the linear relationship between predictive variables and pathology results. P < 0.05 was considered statistically significant. Results: NLR and PLR values were lower in group 1 than group 2 and were found statistically significant between in group 1 and group 2 (p: 0.03 and p: 0.02, respectively). MPV value was found 1.7 times higher in patients who were diagnosed with ASAP pathology than Although there was statistically significant increase in MPV values in logistic regression results, no statistically significant diagnostic value was found. In addition MPV value was found 0.5 times higher in patients who were diagnosed patients with ASAP than prostate cancer group. ROC analysis showed that the optimal threshold was 7.65 femtoliter (sensitivity: 51%; specificity: 30%) and was found to be a statistically significant diagnostic value to distinguish groups 2 and 3. The lowest value of MPV was found in group 3. Conclusions: In cases where the PSA value is insufficient in predicting the pathology result, the effect of NLR, PLR and MPV on differential diagnosis can be kept in mind. While NLR and PLR are more useful in the diagnosis of ASAP, MPV is more effective in the diagnosis of malignancy.
Introduction
Prostate cancer (PCa) is the second most common cancer in men. The gold standard for diagnosis of PCa is transrectal ultrasound guided (TRUS) prostate biopsy. The Prostate-Specific Antigen (PSA) alone is not sufficient in the prediction of the outcomes of the prostate biopsy. For this reason, unnecessary biopsy can be performed in cases with elevation of the PSA such as age-related prostate enlargement or prostate inflammation. Also there is a possibility of detecting prostate cancer at each PSA level and the likelihood of a negative prostate biopsy is increased as the PSA threshold value decreases.
Complete Blood Count (CBC) and its parameters are evaluated before routine prostate biopsy. Many parameters and derivatives such as neutrophil lymphocyte ratio, platelet lymphocyte ratio, and mean platelet volume were demonstrated in the literature with positive predictive results of cancer diagnosis, tumor progression or tissue inflammation level [1] [2] [3] . However, studies on these parameters did not have high-level evidence-based results that prostate cancer guidelines could offer.
We aimed to assess the relationship between CBC parameters and prostate biopsy results in patients with elevation of the PSA and determine the effect of CBC parameters in differential diagnosis of cancer. in 53 patients (25.98%) were included in the study by systematic sampling. The criteria for inclusion in the study were as follows: Digital rectal examination results suggestive or non-suggestive of neoplasia or elevated PSA (>2.5 ng/mL in men) and evaluation of CBC results in the last week before prostate biopsy.
Materials and Methods

Study Population
The criteria for exclusion in the study were as follows: Diesease of coagulopathies, patients with urinary tract infections, individuals who have had surgery in the past year, total number of cores less or more than 10 in prostate biopsy and patients with inadequate data.
Clinical Examination and Biochemical Measurements
Patients' age, TRUS calculated PVs with the ellipse method (length X depth X width X π/6), total PSA (tPSA), free PSA (fPSA), rate of percentage of free to total prostate specific antigen (f/tPSA) rate, PSA density (PSA-D) that was calculated as total PSA (ng/mL/cc) divided by prostate volume (cc), white blood cell (WBC) count, blood neutrophil count (NC), blood lymphocyte count (LC), neutrophil lymphocyte ratio (NLR), mean platelet volume (MPV), platelet (PLT) count and platelet-to-lymphocyte ratio (PLR) were evaluated before the initial biopsy in all patients.
One day before the TRUS guided prostate biopsy, oral administration of 500-mg levofloxacin was started and it was continued until the end. The day of biopsy a rectal enema (250 mL) was performed before the biopsy. The procedure was performed while the patient was in the left lateral position with the thighs flexed. The procedure was performed under the guidance of ultrasound device with a 7.5 mHz biplanar probe.
The biopsy was performed on an outpatient basis in a room equipped with all material necessary for emergency intervention. Sedation and anesthesia were not achieved. 10 minutes before the procedure, periprostatic nerve block was performed in addition to perianal intrarectal lidocain gel. Injections were delivered at the angle between the seminal vesicle and prostate on each side using 5 cc of 2% lidocain. The biopsies were performed by multiple experienced urologists. Standard 10 -12 (both lateral and medial biopsies from the base, medial and apex on the right and left side of the prostatic peripheral zone) core biopsy was performed in prostate biopsies. 
Statistical Analysis
In the analysis of the data, the normality hypothesis was first investigated using 
Results
The mean ages of the patients with benign pathology, ASAP and PCa were 61.92 Table 2 .
tPSA, fPSA, f/tPSA ratio and PSA-D values were found statistically significant between in group 1 and group 3 (p: 0.001, p: 0.03, p: 0.001 and p: 0.001, respectively).PV, tPSA, fPSA, PSA-D and MPV were found statistically significant between in group 2 and group 3 (p: 0.01, p: 0.001, p: 0.02, p: 0.001 and p: 0.04, respectively).
CBC parameters were not found to be statistically significant in the differential diagnosis of group 1 and 3 as a predictor of pathology result (p > 0.05). NLR and PLR were lower in group 1 (2.06 ± 0.7 and 102.55 ± 34.87) than group 2 (2.85 ± 2.64 and 125.88 ± 65.64) were found statistically significant between in group 1 and 2 (p: 0.03 and p: 0.02, respectively). The analysis showed that baseline MPV higher than 7.65 fL indicates the presence of malignity with 51% sensitivity and 30% specificity (Figure 2 ). 
Discussion
Prostate cancer is the most common cancer in men [6] . Transrectal ultrasound (TRUS) guided prostate biopsy is the gold standard for the diagnosis of prostate cancer [7] . The sensitivity of TRUS guided prostate biopsy for the diagnosis of prostate cancer ranges between 49% and 87%, and specificity ranges between 38% and 93% [8] [9] . Several factors may influence the accuracy of biopsy results Age-adjusted incidence of PCa starts in the 50s and peaks in the 70s [10] . In our cohort, patients with benign pathology were found to be at an earlier age in accordance with the literature, and ASAP and malignant pathology results were more common in the later ages together with increasing cellular mutation.
The predictive value of tPSA in the differential diagnosis between benign pathology and ASAP is poor [11] . Ouyang, et al. [12] did not found to demonstrate a direct relationship between ASAP and PSA. In our study, tPSA levels were higher in patients with ASAP than benign pathologies but not statistically significant. Although tPSA, fPSA, f/tPSA ratio and PSA-D did not differ between group 1 and 2 in our cohort, they were significant predictor of positive re-biopsy result in patients with ASAP [13] [25] .
The mean NLR values of patients in our study consistent with literature. Our NLR levels in ASAP were found higher than the results of this study (2.85 ± 2.64), but PLR levels were similar (125.88 ± 65.64). Mean platelet volume (MPV) is commonly used indicator of platelet activation. The range of MPV in Turkish healthy subjects is 8.9 ± 1.4 fL [26] . When the literature is evaluated, it is seen that MPV levels were estimated in genitourinary cancers such as prostate, renal or testicular cancers. Gokcen, et al. [27] et al. found that MPV was significantly lower in testicular cancer group compared to the healthy group. MPV, NLR and PLR may be helpful for prediagnosis of testicular cancers. In another similar study in patients with renal cell carcinoma, MPV was significantly lower in renal cell carcinoma group compared to the control group [28] . In recent years MPV has been used to differentiate PCa from benign prostate tissue. Fu, et al. [29] et al. found that reduced MPV and elevated PSA in patients with PCa have had and the combination of PSA, MPV, and PDW may be clinically useful in distinguishing between PCa and benign prostate tissue. In contrast to genitourinary cancers, MPV values may increase in cases with nonsymptomatic prostatitis [30] . Another study supporting this result, MPV values significantly decreased after treatment in prostatitis. This supports MPV as an inflammation marker [31] . In our study, MPV values were lower than healthy subjects. The lowest value was found in the prostate cancer group (7.74 ± 1.15 fL). The highest value was detected in the ASAP group which is closely related to inflammation (8.29 ± 1.37 fL).
The limitations of the study; evaluation of data retrospectively, not contain large patient cohorts and the absence of an effective parameter or threshold in differentiation of benign and malignant prostate tissue. More studies are needed about complete blood count parameters to predict of biopsy results.
Conclusion
Nowadays, prostate biopsy is used in the differential diagnosis of many factors that cause PSA elevation. However, it is not easy to perform because prostate biopsy is an invasive procedure in patients. Therefore, besides the PSA value, the diagnostic value of additional analyzes is needed. The high values of NLR, PLR and MPV play an effective role in the prediction of ASAP, but the low MPV value supports the possibility of prostate cancer. Considering these results, we recommend that the complete blood count parameters should be examined carefully before prostate biopsy and the possible diagnoses are evaluated in this context.
